{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:57Z","timestamp":1756902177169,"version":"3.44.0"},"reference-count":16,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Sepsis is one of the primary causes of newborn morbidity and mortality, particularly in preterm infants, and coagulase-negative staphylococci (CoNS) is a major cause of bacterial infections in the neonatal intensive care unit (NICU). The treatment of late-onset neonatal staphylococcal sepsis is challenging owing to increased minimum inhibitory concentrations and the potential side effects of vancomycin. Herein, we describe 2 cases of extremely preterm newborns treated with intravenous (IV) ceftaroline (6 mg\/kg\/dose every 8 hours) for late-onset neonatal staphylococcal sepsis. Both cases were diagnosed with bacteremia and treated with ceftaroline. However, one of the patients died, most likely from sepsis or other factors, including chronic lung illness and prematurity, despite sterile blood cultures after starting the ceftaroline treatment. Large-scale randomized studies are required to examine the optimal dosing, safety, and effectiveness of IV ceftaroline for sepsis caused by CoNS in neonates.<\/jats:p>","DOI":"10.5863\/jppt-24-00087","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T19:46:14Z","timestamp":1755114374000},"page":"508-514","source":"Crossref","is-referenced-by-count":0,"title":["Intravenous Ceftaroline in Extremely Premature Neonates With Coagulase-Negative Staphylococci Septicemia: A Report of 2 Cases"],"prefix":"10.5863","volume":"30","author":[{"given":"Suzan S.","family":"Assfour","sequence":"first","affiliation":[{"name":"Clinical Pharmacy Department (SSA, AKH, SOS), King Saud Medical City, Pediatric Infectious Disease Department (FAA), King Saud Medical City, Neonatal Intensive Care Unit (AA, MMA), King Saud Medical City, Obstetrics and Gynaecology Department (TMK), King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad A.","family":"AlMoghaileth","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department (SSA, AKH, SOS), King Saud Medical City, Pediatric Infectious Disease Department (FAA), King Saud Medical City, Neonatal Intensive Care Unit (AA, MMA), King Saud Medical City, Obstetrics and Gynaecology Department (TMK), King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adli","family":"Abdelrahim","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department (SSA, AKH, SOS), King Saud Medical City, Pediatric Infectious Disease Department (FAA), King Saud Medical City, Neonatal Intensive Care Unit (AA, MMA), King Saud Medical City, Obstetrics and Gynaecology Department (TMK), King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal K.","family":"Hassouneh","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department (SSA, AKH, SOS), King Saud Medical City, Pediatric Infectious Disease Department (FAA), King Saud Medical City, Neonatal Intensive Care Unit (AA, MMA), King Saud Medical City, Obstetrics and Gynaecology Department (TMK), King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara O.","family":"Salem","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department (SSA, AKH, SOS), King Saud Medical City, Pediatric Infectious Disease Department (FAA), King Saud Medical City, Neonatal Intensive Care Unit (AA, MMA), King Saud Medical City, Obstetrics and Gynaecology Department (TMK), King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raneem S.","family":"Assfour","sequence":"additional","affiliation":[{"name":"Pharmacy College (RSA), Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanaa M.","family":"Khalil","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department (SSA, AKH, SOS), King Saud Medical City, Pediatric Infectious Disease Department (FAA), King Saud Medical City, Neonatal Intensive Care Unit (AA, MMA), King Saud Medical City, Obstetrics and Gynaecology Department (TMK), King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mountasser M.","family":"Al-Mouqdad","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department (SSA, AKH, SOS), King Saud Medical City, Pediatric Infectious Disease Department (FAA), King Saud Medical City, Neonatal Intensive Care Unit (AA, MMA), King Saud Medical City, Obstetrics and Gynaecology Department (TMK), King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"suppl 2","key":"i2331-348X-30-4-508-b01","series-title":"Early Hum Dev","first-page":"S69","article-title":"Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units","volume":"88","author":"Hornik","year":"2012","unstructured":"Hornik CP, Fort P, Clark RH, et al. Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. Early Hum Dev. 2012;88(suppl 2):S69\u2013S74."},{"issue":"6","key":"i2331-348X-30-4-508-b02","series-title":"Arch Dis Child Fetal Neonatal Ed","first-page":"F547","article-title":"Epidemiology of UK neonatal infections: the neonIN infection surveillance network","volume":"103","author":"Cailes","year":"2018","unstructured":"Cailes B, Kortsalioudaki C, Buttery J, et al. Epidemiology of UK neonatal infections: the neonIN infection surveillance network. Arch Dis Child Fetal Neonatal Ed. 2018;103(6):F547\u2013F553."},{"year":"2016","key":"i2331-348X-30-4-508-b03","unstructured":"TEFLARO (ceftaroline fosamil) for injection [prescribing information]. Allergan; 2016."},{"issue":"8","key":"i2331-348X-30-4-508-b04","series-title":"J Pediatr Pharmacol Ther","first-page":"754","article-title":"Ceftaroline and daptomycin combination antibiotic therapy for a methicillin-resistant Staphylococcus aureus liver abscess in a premature infant","volume":"27","author":"Heger","year":"2022","unstructured":"Heger ML, Al-Sayyad B. Ceftaroline and daptomycin combination antibiotic therapy for a methicillin-resistant Staphylococcus aureus liver abscess in a premature infant. J Pediatr Pharmacol Ther. 2022;27(8):754\u2013759."},{"issue":"2","key":"i2331-348X-30-4-508-b05","series-title":"Pediatrics","first-page":"285","article-title":"Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network","volume":"110","author":"Stoll","year":"2002","unstructured":"Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2 pt 1):285\u2013291."},{"issue":"3","key":"i2331-348X-30-4-508-b06","series-title":"J Clin Neonatol","first-page":"141","article-title":"A retrospective cohort study patient chart review of neonatal sepsis investigating responsible microorganisms and their antimicrobial susceptibility","volume":"7","author":"Al-Mouqdad","year":"2018","unstructured":"Al-Mouqdad M, Alaklobi F, Aljobair F, et al. A retrospective cohort study patient chart review of neonatal sepsis investigating responsible microorganisms and their antimicrobial susceptibility. J Clin Neonatol. 2018;7(3):141\u2013145."},{"issue":"1","key":"i2331-348X-30-4-508-b07","series-title":"Am J Infect Control","first-page":"26","article-title":"Nosocomial infections in a neonatal intensive care unit: incidence and risk factors","volume":"30","author":"Nagata","year":"2002","unstructured":"Nagata E, Brito AS, Matsuo T. Nosocomial infections in a neonatal intensive care unit: incidence and risk factors. Am J Infect Control. 2002;30(1):26\u201331."},{"issue":"6","key":"i2331-348X-30-4-508-b08","series-title":"Eur J Clin Microbiol Infect Dis","first-page":"403","article-title":"Glycopeptide resistance in coagulase-negative staphylococci","volume":"19","author":"Biavasco","year":"2000","unstructured":"Biavasco F, Vignaroli C, Varaldo PE. Glycopeptide resistance in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis. 2000;19(6):403\u2013417."},{"issue":"2","key":"i2331-348X-30-4-508-b09","series-title":"Int J Antimicrob Agents","first-page":"106","article-title":"Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review","volume":"36","author":"Kocher","year":"2010","unstructured":"Kocher S, Muller W, Resch B. Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review. Int J Antimicrob Agents. 2010;36(2):106\u2013110."},{"issue":"3","key":"i2331-348X-30-4-508-b10","series-title":"J Antimicrob Chemother","first-page":"643","article-title":"Daptomycin in paediatrics: current knowledge and the need for future research","volume":"70","author":"Principi","year":"2015","unstructured":"Principi N, Caironi M, Venturini F, et al. Daptomycin in paediatrics: current knowledge and the need for future research. J Antimicrob Chemother. 2015;70(3):643\u2013648."},{"issue":"5","key":"i2331-348X-30-4-508-b11","series-title":"Ther Drug Monit","first-page":"619","article-title":"Evaluation of target attainment of vancomycin area under the curve in children with methicillin-resistant Staphylococcus aureus bacteremia","volume":"37","author":"Hahn","year":"2015","unstructured":"Hahn A, Frenck RW Jr, Allen-Staat M, et al. Evaluation of target attainment of vancomycin area under the curve in children with methicillin-resistant Staphylococcus aureus bacteremia. Ther Drug Monit. 2015;37(5):619\u2013625."},{"issue":"5","key":"i2331-348X-30-4-508-b12","series-title":"Pediatr Infect Dis J","first-page":"511","article-title":"Clinical experience with daptomycin for the treatment of gram-positive infections in children and adolescents","volume":"35","author":"Syriopoulou","year":"2016","unstructured":"Syriopoulou V, Dailiana Z, Dmitriy N, et al. Clinical experience with daptomycin for the treatment of gram-positive infections in children and adolescents. Pediatr Infect Dis J. 2016;35(5):511\u2013516."},{"issue":"3","key":"i2331-348X-30-4-508-b13","series-title":"Clin Infect Dis","first-page":"e18","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18\u2013e55."},{"issue":"1","key":"i2331-348X-30-4-508-b14","series-title":"Infect Dis Ther","first-page":"57","article-title":"Use of ceftaroline fosamil in children: review of current knowledge and its application","volume":"6","author":"Yim","year":"2017","unstructured":"Yim J, Molloy LM, Newland JG. Use of ceftaroline fosamil in children: review of current knowledge and its application. Infect Dis Ther. 2017;6(1):57\u201367."},{"issue":"5","key":"i2331-348X-30-4-508-b15","series-title":"Pediatr Infect Dis J","first-page":"411","article-title":"Phase 2 study of the safety, pharmacokinetics and efficacy of ceftaroline fosamil in neonates and very young infants with late-onset sepsis","volume":"39","author":"Bradley","year":"2020","unstructured":"Bradley JS, Stone GG, Chan PLS, et al. Phase 2 study of the safety, pharmacokinetics and efficacy of ceftaroline fosamil in neonates and very young infants with late-onset sepsis. Pediatr Infect Dis J. 2020;39(5):411\u2013418."},{"issue":"4","key":"i2331-348X-30-4-508-b16","series-title":"J Pediatric Infect Dis Soc","first-page":"342","article-title":"Pharmacokinetics of ceftaroline in a preterm infant with methicillin-resistant Staphylococcus aureus pneumonia","volume":"7","author":"Salerno","year":"2018","unstructured":"Salerno SN, Bernhardt J, Laughon M, et al. Pharmacokinetics of ceftaroline in a preterm infant with methicillin-resistant Staphylococcus aureus pneumonia. J Pediatric Infect Dis Soc. 2018;7(4):342\u2013345."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/4\/article-p508.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/4\/article-p508.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/4\/article-p508.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T19:46:15Z","timestamp":1755114375000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/4\/article-p508.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":16,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.5863\/jppt-24-00087","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}